等待开盘 10-13 09:30:00 美东时间
+0.005
+0.41%
Geron (NASDAQ:GERN) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full ...
10-08 16:19
Geron Corporation granted stock options to 9 new employees on September 17, 2026, totaling 821,250 shares. The options have an exercise price of $1.32 per share, a 10-year term, and vest over four years. The equity awards were approved by Geron’s Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and the 2018 Inducement Award Plan. Geron is a biopharmaceutical company focused on blood cancer treatments, with its medicine RYTELO® approved...
09-18 20:01
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be r...
09-03 03:58
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breach...
09-03 01:36
Geron Corporation granted stock options to six new employees on August 17, 2026, totaling 311,250 shares with an exercise price of $1.53 per share, equal to the closing price on the grant date. The options vest over four years, with 12.5% vesting after six months of employment and the remainder vesting quarterly over the next 42 months, contingent on continued employment. The awards were made under the Nasdaq Listing Rule 5635(c)(4) and Geron’s 2...
08-18 20:01
Geron Corporation (($GERN)) has held its Q2 earnings call. Read on for the main...
08-17 08:27
Geron Corporation reported Q2 2026 financial results, achieving $57.5 million in net product revenue for RYTELO® (imetelstat), a 11% increase from Q1 2026. The company reaffirmed its 2026 guidance, expecting net product revenue between $220 million and $240 million, with total operating expenses in the range of $230 million to $240 million. Geron ended Q2 2026 with $327 million in cash, cash equivalents, restricted cash, and marketable securities...
08-05 11:00
Geron Corporation granted stock options to five new employees, totaling 202,500 shares, as an inducement for employment. The options have an exercise price of $1.44 per share, a 10-year term, and vest over four years, with 12.5% vesting after six months and the remainder vesting quarterly. The awards were made under Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan. Geron is a biopharmaceutical company focused on blood cancer ...
07-22 20:01
Geron Corporation, a biopharmaceutical company focused on blood cancer treatments, will release its Q2 2026 financial results and business highlights on August 5, 2026, via press release. A conference call and webcast will follow at 8:00 a.m. ET. Geron's lead product, RYTELO® (imetelstat), is approved for certain myelodysplastic syndromes and is being tested in myelofibrosis. More info available on www.geron.com.
07-22 11:00
7月10日,香港政府公布,再度委任黄杰龙教授为能源咨询委员会主席,并委任18位社会人士为委员会成员,任期两年,由2026年7月15日起生效。
07-10 13:44